ArticleFrontiers in public health2025

Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer.

Longfeng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.